StockData
Journey Medical Corp logo

Journey Medical Corp (DERM) stock

DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3033% below fair value
$3.90+0.20 (+5.41%)

Close on Nov 17, 2026Market cap $110.08MP/E –Yield –

Journey Medical r&d expenses

Research and development expenses are spending on new products and technology.

Journey Medical's R&D Expenses for the twelve months ending Dec 31, 2025 was $480.00K, down 95.1% year over year. For fiscal 2025 it was $480.00K, down 95.1% from the year before. The highest annual figure on record is $10.94M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$480.00K-95.1%
FY2024Dec 31, 2024$9.86M+30.7%
FY2023Dec 31, 2023$7.54M-31.1%
FY2022Dec 31, 2022$10.94M+299.5%
FY2021Dec 31, 2021$2.74M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$54.00K+38.5%
Q4 FY2025Dec 31, 2025$154.00K-29.4%
Q3 FY2025Sep 30, 2025$287.00K-65.9%
Q2 FY2025Jun 30, 2025$0-100.0%
Q1 FY2025Mar 31, 2025$39.00K-99.5%
Q4 FY2024Dec 31, 2024$218.00K-85.5%
Q3 FY2024Sep 30, 2024$842.00K-62.2%
Q2 FY2024Jun 30, 2024$913.00K-78.5%
Q1 FY2024Mar 31, 2024$7.88M+180.4%
Q4 FY2023Dec 31, 2023$1.51M-42.3%
Q3 FY2023Sep 30, 2023$2.23M+76.1%
Q4 FY2022Dec 31, 2022$4.26M+113.7%
Q3 FY2022Sep 30, 2022$2.81M+291.6%
Q2 FY2022Jun 30, 2022$2.61M+8896.6%
Q1 FY2022Mar 31, 2022$1.27M–
Q4 FY2021Dec 31, 2021$1.99M–
Q3 FY2021Sep 30, 2021$718.00K–
Q2 FY2021Jun 30, 2021$29.00K–

More Journey Medical figures

See a number that looks wrong?